Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Recurrent Malignant Glioma Pipeline Drugs Market Report Overview
Recurrent malignant glioma is defined as the recurrence of a tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy.
The Recurrent Malignant Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects.
Recurrent Malignant Glioma Pipeline Drugs Market Segmentation by Targets
Some of the targets in the Recurrent Malignant Glioma pipeline are Cells Expressing Ephrin Type A Receptor 2, 3-Beta Hydroxysteroid Delta8, Delta7 Isomerase, Cells Expressing Epidermal Growth Factor Receptor, And Cells Expressing Ganglioside GD2 among others. Cells Expressing Ephrin Type A Receptor 2 was the largest target in the pipeline.
Recurrent Malignant Glioma Pipeline Drugs Market Analysis, by Targets
For more Recurrent Malignant Glioma pipeline drugs market target insights, download a free report sample
Recurrent Malignant Glioma Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the mechanisms of action in the Recurrent Malignant Glioma pipeline drugs market are Cytotoxic To Cells Expressing Ephrin Type A Receptor 2, 3-Beta Hydroxysteroid Delta8, Delta7 Isomerase Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, and Cytotoxic To Cells Expressing Ganglioside GD2 among others. Cytotoxic To Cells Expressing Ephrin Type A Receptor 2 was the leading MoA in the pipeline.
Recurrent Malignant Glioma Pipeline Drugs Market Analysis, by Mechanisms of Action
For more MoA insights into the Recurrent Malignant Glioma pipeline drugs market, download a free report sample
Recurrent Malignant Glioma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Recurrent Malignant Glioma pipeline drugs market are oral, intravenous, intratumor, and intracavity among others. The majority of the pipeline drugs followed the intravenous route of administration.
Recurrent Malignant Glioma Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Recurrent Malignant Glioma pipeline drugs market, download a free report sample
Recurrent Malignant Glioma Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Recurrent Malignant Glioma pipeline drugs market are small molecule, monoclonal antibody, gene-modified cell therapy, and cell therapy among others. Small molecule was the leading molecule type in the pipeline.
Recurrent Malignant Glioma Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Recurrent Malignant Glioma pipeline drugs market, download a free report sample
Recurrent Malignant Glioma Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Recurrent Malignant Glioma pipeline drugs market are Candel Therapeutics Inc, Hebei Senlang Biotechnology Co Ltd, Immunomic Therapeutics Inc, and Moleculin Biotech Inc among others.
Recurrent Malignant Glioma Pipeline Drugs Market Analysis by Key Companies
To know more about the Recurrent Malignant Glioma pipeline drugs market companies, download a free report sample
Recurrent Malignant Glioma Pipeline Drugs Market Report Overview
Key Targets | Cells Expressing Ephrin Type A Receptor 2, 3-Beta Hydroxysteroid Delta8, Delta7 Isomerase, Cells Expressing Epidermal Growth Factor Receptor, and Cells Expressing Ganglioside GD2 |
Key Mechanism of Actions | Cytotoxic to Cells Expressing Ephrin Type A Receptor 2, 3-Beta Hydroxysteroid Delta8, Delta7 Isomerase Inhibitor, Cytotoxic to Cells Expressing Epidermal Growth Factor Receptor, and Cytotoxic to Cells Expressing Ganglioside GD2 |
Key Routes of Administration | Oral, Intravenous, Intratumor, and Intracavity |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, and Cell Therapy |
Key Companies | Candel Therapeutics Inc, Hebei Senlang Biotechnology Co Ltd, Immunomic Therapeutics Inc, and Moleculin Biotech Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Hebei Senlang Biotechnology Co Ltd
Immunomic Therapeutics Inc
Moleculin Biotech Inc
Oblato Inc
PharmAbcine Inc
Smerud Medical Research International AS
Stella Pharmaceuticals Pvt Ltd
Sumitomo Pharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Recurrent Malignant Glioma pipeline drugs market?
Some of the key targets of the Recurrent Malignant Glioma pipeline drugs market are cells expressing ephrin type A receptor 2, 3-beta hydroxysteroid delta8, delta7 isomerase, cells expressing epidermal growth factor receptor, and cells expressing ganglioside GD2.
-
What are the key mechanisms of action in the Recurrent Malignant Glioma pipeline drugs market?
Some of the key mechanisms of action in the Recurrent Malignant Glioma pipeline drugs market are cytotoxic to cells expressing ephrin type A receptor 2, 3-beta hydroxysteroid delta8, delta7 isomerase inhibitor, cytotoxic to cells expressing epidermal growth factor receptor, and cytotoxic to cells expressing ganglioside GD2.
-
What are the key routes of administration in the Recurrent Malignant Glioma pipeline drugs market?
The key routes of administration in the Recurrent Malignant Glioma pipeline drugs market are oral, intravenous, intratumor, and intracavity.
-
What are the key molecule types in the Recurrent Malignant Glioma pipeline drugs market?
The molecule types in the Recurrent Malignant Glioma pipeline drugs market are small molecule, monoclonal antibody, gene-modified cell therapy, and cell therapy.
-
Which are the key companies in the Recurrent Malignant Glioma pipeline drugs market?
Some of the key companies in the Recurrent Malignant Glioma pipeline drugs market are Candel Therapeutics Inc, Hebei Senlang Biotechnology Co Ltd, Immunomic Therapeutics Inc, and Moleculin Biotech Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.